PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA

May 1, 2008, 00:00
10.1016/S1098-3015(10)70785-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)70785-3/fulltext
Title : PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70785-3&doi=10.1016/S1098-3015(10)70785-3
First page :
Section Title :
Open access? : No
Section Order : 531
Categories :
Tags :
Regions :
ViH Article Tags :